The Max Foundation Welcomes New Board Member, Curt Malloy
The Max Foundation is pleased to welcome Curt Malloy as the newest member of our Executive Board. Curt, a fellow advocate for people facing cancer around the world, has been a strong supporter of our work for many years throughout his active engagement in global health.
Curt currently serves as the Chief Operating Officer at Cancer Research And Biostatistics (CRAB) in Seattle, where he leads data management, project management, clinical monitoring, and regulatory. He is a co-leader of CRAB’s Latin America Initiative, which was formed with the intention of providing clinical research training programs for clinical investigators and statisticians in Latin America and identifying clinical research opportunities.
Prior to joining CRAB, Curt was the operational leader for the Fred Hutch Vaccine and Infectious Disease Division, while also serving on the boards of their global research initiatives in South Africa, Uganda, and China. Prior to the Fred Hutch, Curt served for ten years in various leadership positions at the Infectious Disease Research Institute. Curt has a Masters of Public Health from Columbia University School of Public Health and earned a Juris Doctor with a focus on intellectual property from Seattle University School of Law. He is fluent in Spanish and is particularly passionate about Latin America, social and health equity and planetary health.
Pat Garcia-Gonzalez, CEO of The Max Foundation said of Curt’s appointment, “It is well known that The Max Foundation has a strong historical connection to Latin America given that helping families there was the focus of our original mission. Curt has an impressive background that promises to only strengthen our resolve in serving cancer patients in Latin America and across the globe.”
We are thrilled to be able to leverage Curt’s deep experience serving on NGO boards, his expertise in the field of cancer research, and his strong commitment to global health—all to bring dignity and hope to people facing cancer around the world.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….
UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries
The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs) and to help countries develop the capacity for their proper use. It is estimated that less than….
The Max Foundation’s access program exceeds 10 million daily doses of cancer treatment distributed to patients worldwide
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
